Success Metrics

Clinical Success Rate
78.5%

Based on 504 completed trials

Completion Rate
79%(504/642)
Active Trials
273(23%)
Results Posted
54%(271 trials)
Terminated
138(11%)

Phase Distribution

Ph phase_1
287
24%
Ph early_phase_1
7
1%
Ph not_applicable
22
2%
Ph phase_2
666
55%
Ph phase_3
198
16%
Ph phase_4
11
1%

Phase Distribution

294

Early Stage

666

Mid Stage

209

Late Stage

Phase Distribution1191 total trials
Early Phase 1First-in-human
7(0.6%)
Phase 1Safety & dosage
287(24.1%)
Phase 2Efficacy & side effects
666(55.9%)
Phase 3Large-scale testing
198(16.6%)
Phase 4Post-market surveillance
11(0.9%)
N/ANon-phased studies
22(1.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.6%

504 of 676 finished

Non-Completion Rate

25.4%

172 ended early

Currently Active

273

trials recruiting

Total Trials

1,205

all time

Status Distribution
Active(345)
Completed(504)
Terminated(172)
Other(184)

Detailed Status

Completed504
unknown182
Recruiting172
Terminated138
Active, not recruiting101
Not yet recruiting70

Development Timeline

Analytics

Development Status

Total Trials
1205
Active
273
Success Rate
78.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (0.6%)
Phase 1287 (24.1%)
Phase 2666 (55.9%)
Phase 3198 (16.6%)
Phase 411 (0.9%)
N/A22 (1.8%)

Trials by Status

completed50442%
terminated13811%
recruiting17214%
enrolling_by_invitation20%
withdrawn343%
active_not_recruiting1018%
not_yet_recruiting706%
unknown18215%
suspended20%

Recent Activity

Clinical Trials (1,205)

Showing 20 of 1,205 trialsScroll for more
NCT06269978Phase 1

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

Active Not Recruiting
NCT05564377Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
NCT05502393Phase 1

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Active Not Recruiting
NCT06469944Phase 1

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Recruiting
NCT06624085Phase 1

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active Not Recruiting
NCT05139017Phase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting
NCT06997497Phase 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Recruiting
NCT07043400Phase 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT07748611Phase 2

SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

Not Yet Recruiting
NCT05171647Phase 3

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Active Not Recruiting
NCT06447636Phase 2

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Active Not Recruiting
NCT07283939Not Applicable

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Recruiting
NCT05677490Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting
NCT07490301Phase 2

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
NCT02912559Phase 3

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Active Not Recruiting
NCT04847063Phase 1

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Recruiting
NCT05863195Phase 3

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting
NCT07737600Phase 1

A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

Not Yet Recruiting
NCT05564403Phase 2

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Active Not Recruiting
NCT06820463Phase 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
1,205